Shanghai Junshi Biosciences Co (Shanghai Junshi Biosciences Co) 3-Year Revenue Growth Rate : -10.10% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shanghai Junshi Biosciences Co 3-Year Revenue Growth Rate?

Shanghai Junshi Biosciences Co's Revenue per Share for the three months ended in Mar. 2024 was $0.05.

During the past 12 months, Shanghai Junshi Biosciences Co's average Revenue per Share Growth Rate was -82.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -10.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 179.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 8 years, the highest 3-Year average Revenue per Share Growth Rate of Shanghai Junshi Biosciences Co was 1302.80% per year. The lowest was -10.10% per year. And the median was 468.30% per year.

Competitive Comparison of Shanghai Junshi Biosciences Co's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's 3-Year Revenue Growth Rate falls into.

Shanghai Junshi Biosciences Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Shanghai Junshi Biosciences Co (OTCPK:SHJBF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Shanghai Junshi Biosciences Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (Shanghai Junshi Biosciences Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (OTCPK:SHJBF) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

01877:Hong Kong 8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (Shanghai Junshi Biosciences Co) Headlines

From GuruFocus

Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab

By PRNewswire PRNewswire • 02-03-2021

Junshi Biosciences, Legend Biotech and Zai Lab Are 3 Top Chinese Biotechs

By Barry Cohen Barry Cohen • 11-19-2020

Shanghai Junshi's Anti-Covid-19 Drug Hits Phase 3 Clinical Trials

By Alberto Abaterusso • 11-23-2021